Background: Amyloidosis is a rare complication of non-Hodgkin's lymphoma. Most of the reported patients have had systemic amyloidosis and have died as a result of complications of this disease.
Introduction
Amyloidosis is a heterogeneous condition in which the extracellular deposition of characteristic fibrillar material with typical staining properties occurs. Amyloid fibrils are now known to be formed from many different protein components, each associated with a different underlying disease process [1, 2] . In light chain derived amyloid (AL) the major protein constituent of the amyloid consists of intact monoclonal immunoglobulin light chains (Bence Jones proteins (BJP)), fragments from their amino terminal (variable) region or both [2] . There is a propensity for amyloid to involve the walls of small blood vessels and the tissue deposition is typically widespread, with common sites of involvement in AL being the kidney, heart, tongue, gastrointestinal tract, skin and nerves [1] . In most cases of AL there is an associated clonal B-cell proliferation. This is often histologically occult although a monoclonal plasmacytosis has been noted in the bone marrow in some instances [3] . About 80% of these patients have an identifiable M-protein in the serum, urine or both [2] .
Non-Hodgkins lymphomas have rarely been associated with the development of amyloidosis [4] [5] [6] [7] and previously reported cases have described widespread deposition of amyloid in a pattern typical of primary systemic amyloidosis. We report here 2 cases of nonHodgkins lymphoma (NHL) in which local deposition of light chain derived amyloid (AL) occurred in lymph nodes (both cases) and also in bone marrow (one case), without evidence of systemic amyloidosis.
Materials and methods
Lymph nodes were fixed in 10% formalin for 24 hours. The bone marrow trephine was similarly fixed and this was followed by a decalcification step in 10% formic acid for a further 48 hours. Sections of paraffin embedded tissue were stained with hematoxylin and eosin (H and E) and Congo red. Immunohistochemistry was was performed on the sections using mouse monoclonal antibodies to human kappa (K) and lambda (X) light chains and anti human IgG and IgM (all antibodies from Dako). The sections were then further treated with a standard streptavidin biotin complex immunoperoxidase staining method [8] . Replacement of the primary antiserum with an irrelevant mouse monoclonal antibody provided a negative control. Reactive plasma cells in the tissue provided an internal positive control.
Case reports

Patient 1
A 56-year-old man presented in 1990 with painless lymphadenopathy in the right cervical region. A lymph node biopsy revealed extensive amyloid deposits surrounded by an outer rim of lymphoplasmacytic lymphoma ( Figure 1 However, subsequently his lymphadenopathy progressed and his serum IgM and urinary BJP levels began to rise again. A repeat bone marrow biopsy in May 1992 showed no evidence of lymphoma or amyloid deposition. A second lymph node biopsy revealed extensive replacement of the node by amyloid deposits with associated lymphoplasmacytic lymphoma. There was no clinical evidence of systemic amyloidosis and renal function remained normal. Neither an echocardiogram nor a rectal biopsy showed evidence of amyloid deposition in these organs. Between May 1992 and April 1995, the patient received 3 courses of combination chemotherapy; intravenous cyclophosphamide, etoposide and vincristine with oral prednisolone was given on the first occasion and oral cyclophosphamide and etoposide on subsequent occasions. Each course was associated with a minor reduction in the size of all lymph nodes and a transient fall or no change in the urinary BJP and serum IgM levels ( Figure 3 ). In July 1995 he received radiotherapy to the left axilla because of bulky uncomfortable disease at this site with no benefit.
At present the patient has persisting bulky peripheral and hilar lymphadenopathy, normal renal function (serum creatinine 86 umol/1), no evidence of cardiac amyloid (assessed by echocardigraphy, January 1996) and no clinical evidence of other organ involvement by amyloidosis.
Patient 2
A 64-year-old man presented in 1985 with localised left inguinal lymphadenopathy and an excision biopsy demonstrated infiltration of the lymph nodes with lymphoplasmacytic lymphoma. No treatment was given as he was asymptomatic. Over the next 12 months he developed generalised lymphadenopathy, became lethargic, lost 10 kg in weight and in September 1986 he sustained a pathological fracture of the right femoral neck. An arthroplasty was performed and histology of the femoral head and neck showed extensive deposition of amyloid within the bone adjacent to areas of infiltration by lymphoplasmacytic lymphoma. A posterior iliac crest bone marrow biopsy showed diffuse infiltration by lymphoplasmacytic lymphoma but no evidence of amyloid deposition. Immunohistochemistry showed IgM positive tumour cells with K light chain restriction. A full blood count showed a hemoglobin of 9.8 g/dl, white cell count 1.9 x 10 9 /l and platelets 194 x 1O 9 /1. The patient next developed rapidly progressive axillary lymphadenopathy and a lymph node biopsy from this site showed extensive replacement by amyloid with surrounding lymphoplasmacytic lymphoma which had the same immunoglobulin phenotype as that seen in the bone marrow. The amyloid deposits stained with an anti-K monoclonal antibody. Free monoclonal K light chains were found in the serum and urine (2.8 g/24 hours) by immunoelectrophoresis. The serum creatinine was 96 umol/1. An abdominal ultrasound showed splenomegaly and enlarged iliac lymph nodes. There was no clinical evidence of systemic amyloidosis, however, neither echocardiogram, rectal biopsy nor abdominal fat aspirate were performed.
The patient received one cycle of oral chlorambucil in November 1986 with no clinical response or reduction in the serum or urinary light chain levels, but suffered prolonged myelosuppression and this treatment was discontinued. He was subsequently treated with oral prednisolone 20 mg daily for 2 months with no response. As his major complaint was of painful bulky inguinal lymphadenopathy he was treated with radiotherapy to both inguinal regions (4000 cGy) in June 1987 which led to resolution of the local discomfort, but no significant change in the size of the inguinal masses.
During the next 8 years slow progression of the patient's lymphadenopathy occurred, associated with increasing discomfort. In May 1989, a further lymph node mass was excised from the left axilla and in March 1994 surgical debulking of his massively enlarged inguinal nodes was performed. Histological examination of the nodes on both occasions revealed extensive amyloid deposition. At last review in June 1995, the patient had persistent generalised lymphadenopathy. Although K light chains continue to be excreted in the urine (the level has not been quantitated subsequently), free light chains are no longer detectable in the serum. His renal function has remained normal. Over this long period of follow-up he has not developed any features of systemic amyloidosis.
Discussion
Lymphadenopathy due to amyloid infiltration is extremely uncommon [9] . It is the presenting manifestation of systemic amyloidosis in only 4% of patients [10] . Isolated AL involving lymph nodes as the sole manifestation is very rare with only 3 cases reported in the literature [11, 12, 13] . Amyloidosis has only rarely been reported in association with B-cell neoplasms other than multiple myeloma [4] [5] [6] [7] . It has been reported to occur in association with Waldenstrom's macroglobulinemia but is rarely associated with the presence of an IgM paraprotein (only 4.4% of all cases of AL) [7, 14] . Whilst amyloid deposition was noted in lymph nodes in some of cases, nearly all of these patients had evidence of systemic amyloid deposition which was irreversible and associated with a poor prognosis, the majority of patients dying of complications of systemic amyloidosis.
Lytic bone lesions due to large amyloid deposits also occur infrequently. In a series of 178 patients with systemic amyloidosis which was not associated with myeloma no osteolytic lesions were found [10] . Khojasteh et al. have reviewed this subject and found 9 reported cases with histologically proven amyloid deposits in bone [15] . This may predispose to pathological fracture [16] as occurred in one of our patients.
Most patients with B-cell lymphoma have detectable monoclonal immunoglobulin in the serum that is identical in isotype to that borne by the malignant cells [17] . Whether the light chain fragments that form AL represent synthetic [18] or catabolic products [19] has not yet been established, but amyloidosis develops in only a small percentage of patients with light chain overproduction. This may be because only some light chains are inherently amyloidogenic, or because other pathological factors in the host induce amyloid development. In vitro, 15%-20% of light chains will precipitate as fibrillar material resembling amyloid after proteolytic digestion. This amyloidogenic property is associated with the variable region of the light chain and is seen more commonly with lambda (X.) than K monoclonal light chains [20] in keeping with the clinical observation that in AL the light chain class is more frequently X than K (2 :1) [1] . Thus it is of interest that both of our patients had monoclonal K light chains.
Little is known about the factors that determine the characteristic tissue distribution of different types of amyloid. In systemic (AL) amyloidosis the amyloid deposits may be derived from a circulating precursor whose deposition is determined by its affinity for certain tissues or alternatively, monoclonal light chains may be processed immediately adjacent to sites of synthesis to form amyloid fibrils [21] . Both of our patients had only localised amyloid deposits despite the presence of circulating monoclonal light chains. These localized deposits of amyloid in lymph nodes and bone occurred adjacent to lymphoma and were derived from monoclonal light chains of the same class as those expressed by the lymphoma cells. These findings suggest that there was local production and deposition of amyloid from monoclonal light chains synthesised by the lymphoma cells. However, amyloid deposits were not seen at all sites where lymphoma was demonstrated raising the possibility that other local factors contributed to the formation of amyloid.
Although the clinical course of our 2 patients has been indolent, cytotoxic treatment directed against the monoclonal immunoglobulin light chain producing B-cell clone has not prevented amyloid accumulation and progression of the patient's lymphadenopathy, in keeping with previous reports of the limited efficacy of cytotoxic therapy in primary systemic amyloidosis [22] . A recent report demonstrating that the anthracycline 4'-iodo-4'-deoxydoxorubicin (I-DOX) can induce amyloid resorption and associated clinical responses independent of a cytotoxic effect on the clone producing the amyloid precursor suggests that this may be a more effective therapy [23] . Local radiotherapy did not produce a reduction in the size of the lymphadenopathy in either patient and some concern over this modality of treatment is raised by a previous report of NHL transforming to amyloidoma following treatment with radiotherapy [24] , suggesting that in some circumstances radiotherapy may enhance amyloid deposition.
In conclusion, these 2 patients with lymphoplasmacytic lymphoma presented with lymphadenopathy due to local amyloid deposition. They have been followed now for 5 and 9 years, respectively, and neither has developed clinical evidence of systemic amyloidosis. Treatment with cytotoxic therapy and radiotherapy were ineffective in preventing progression of amyloid deposits and new, innovative therapies should be tested in this condition.
